- Research article
- Open Access
- Open Peer Review
Early life environment and natural history of inflammatory bowel diseases
BMC Gastroenterologyvolume 14, Article number: 216 (2014)
Early life exposures may modify risk of inflammatory bowel diseases (IBD; Crohn’s disease (CD), ulcerative colitis (UC)). However, the relationship between early life exposures and natural history of IBD has not been previously examined.
This single center study included patients with CD or UC recruited in a prospective IBD registry. Enrolled patients completed a detailed environmental questionnaire that assessed various early life environmental exposures. Our primary outcome was requirement for disease-related surgery in CD and UC. Logistic regression models defined independent effect of early life exposures, adjusting for potential confounders.
Our study included 333 CD and 270 UC patients. Just over half were female with a median age at diagnosis of 25 years. One-third of the cohort had history of bowel surgery (31%) and nearly half had used at least one biologic agent (47%). Among those with CD, being breastfed was associated with reduced risk of CD-related surgery (34% vs. 55%), while childhood cigarette smoke exposure was associated with increased risk. On multivariate analysis, history of being breastfed (odds ratio (OR) 0.21, 95% confidence interval [CI] 0.09–0.46) and cigarette smoke exposure as a child (OR 2.17, 95% CI 1.10–4.29) remained independently associated with surgery. None of the early life variables influenced disease phenotype or outcome in UC.
A history of being breastfed was associated with a decreased risk while childhood cigarette smoke exposure was associated with an increased risk of surgery in patients with CD. Further investigation to examine biological mechanisms is warranted.
Inflammatory bowel disease (IBD), which comprises Crohn’s disease (CD) and ulcerative colitis (UC), are chronic immune mediated diseases characterized by a dysregulated immune response to commensal flora in a genetically susceptible host . The expanded set of 163 distinct risk alleles for CD and UC together explain less than one-third of the heritability of disease . The relatively recent secular increase in disease incidence  and the changes in disease risk occurring with migration , suggest an important role for the modifiable external environment in pathogenesis. Growing literature demonstrating microbial dysbiosis in patients with IBD with reduced diversity ,-, decreased representation of potentially protective bacteria like Faecalibacterium prausnitzii  and increased frequency of potentially pathogenic bacteria in certain disease subsets like ileal CD  suggests that one possible mechanism through which the environment influences disease risk may be through the microbiome.
Given the peak age of incidence of IBD in childhood and early adulthood, the role of early life environmental factors is of considerable interest. The spectrum of risk factors examined range from gestational age and mode of delivery to breastfeeding, antibiotic use, exposure to farm animals or pets, and cigarette smoke, all of which have variably been demonstrated to modify risk of CD or UC -. It is of note that few studies have examined whether such early life environmental exposures modify natural history of disease by influencing disease phenotype or severity. Given the growing data on the role of microbiome in determining natural history of disease, it is indeed plausible that such early life exposures may influence disease phenotype and outcomes beyond incident disease. A particularly promising such factor is breastfeeding. Breastfeeding is known to have protective benefits for infants due to the immunomodulatory properties of breast milk - and the effect of human milk oligosaccharides on the infant microbiota. Furthermore, secretory antibodies in breast milk promote intestinal homeostasis, regulate gut microbial composition, and modulate host gene expression -.
Examining the influence of these early life environmental factors on disease outcome could shed light on its interplay with microbiome, potentially leading to novel therapies targeting intestinal flora. Consequently, we performed this study using a large, well-phenotyped cohort of IBD patients to investigate the effects of early environmental exposures on disease course in both CD and UC.
The study population consisted of adult patients enrolled in the Prospective Registry in IBD Study at Massachusetts General Hospital (PRISM). This is a single center ongoing patient registry that aims to understand the causes of IBD and factors affecting disease progression. Patients were approached during their regularly scheduled clinic visits at the MGH Crohn’s and Colitis Center. Study research coordinators obtained consent and medical history was obtained and confirmed by review of the electronic medical record.
Environmental questionnaires including ten questions on early life exposures were distributed to patients during regularly scheduled clinic visits subsequent to enrollment. The first wave of questionnaires was distributed in 2010 (n = 348) and the second wave to an additional set of patients was distributed during January-June 2014 (n = 255). Early life exposures included questions on gestational age, history of breastfeeding, exposure to cigarette smoke in childhood, treatment with antibiotics, hospitalization, and exposure to pets or farm animals (Additional file 1). Those who answered “Not sure” for any of the exposures were treated as missing for that variable.
Covariates and outcomes
Information on age at diagnosis, demographics, family history of IBD, and disease behavior, location or extent was obtained during the study visit. Age at diagnosis was assessed as <16 years (A1), 17 to 40 years (A2), >40 years (A3) according to the Montreal classification . Disease location was characterized as terminal ileum (L1), colon (L2), ileocolon (L3) or upper gastrointestinal (L4) disease. In CD, behavior was characterized as inflammatory (B1), stricturing (B2), and penetrating (B3), each with the potential modifier of perianal involvement. Disease extent in UC was characterized as proctitis (E1), left-sided colitis (E2), pancolitis (E3).
Our primary outcome was IBD-related bowel resection for both CD and UC while our secondary outcome included need for anti-tumor necrosis factor biologic therapy (infliximab, adalimumab, certolizumab pegol). IBD-related surgery was selected as our primary outcome as this is a more robust and hard endpoint that is less influenced by physician practice variation. Disease characteristics and outcomes were confirmed by the treating physician.
The data was analyzed using Stata 13.0 (StataCorp, College Station, TX). Separate analyses were conducted for CD and UC. Patients with indeterminate colitis were grouped with UC owing to small numbers of the former. Continuous variables were summarized using means and standard deviations while categorical variables were expressed as proportions and compared using the chi-square test. We first performed univariate analysis comparing the environmental risk factors to our primary and secondary outcomes of interest. Multivariate regression models adjusting for disease specific covariates including phenotype and duration since diagnosis were used to identify the independent association of the exposures with our outcome of interest. This also allowed for exploration of whether the early life environmental influences exerted their effect through modification of disease phenotype. A p-value of <0.05 was considered statistically significant. Ethical approval for this study was obtained from the Institutional Review Board of Partners Healthcare (2004P001067). All patients enrolling in PRISM provided informed consent for participation in the registry.
A total of 603 patients completed questionnaires on early life exposures (333 CD; 270 UC/IC). Just over half the cohort was female (54%), and 23% had family history of IBD in a first-degree relative. The median age at diagnosis of IBD was 25 years (interquartile range (IQR) 18 – 35 years) with median disease duration of 9 years at the time of enrollment (IQR 4 – 16 years). Nearly half of those with CD had inflammatory disease (44%), a third had penetrating disease (36%) while the remainder had stricturing phenotype. The most common location was ileocolonic (51%) followed by colon alone (24%) or ileal alone (18%). Over half of those with UC (57%) had pancolitis. In the entire cohort, 186 patients (31%) had at least one IBD-related surgery, two-thirds had used immunomodulators (65%) and half required biologics (46%). Table 1 describes the frequency of occurrence of various environmental exposures. Just over half the cohort had a history of being breastfed in infancy. Few were delivered via Caesarean section, required hospitalization in childhood, or grew up on a farm.
On univariate analysis, a history of being breastfed was associated with reduced risk of surgery in CD (odds ratio (OR) 0.42, 95% confidence interval (CI) 0.25 – 0.68) while childhood cigarette smoke exposure was associated with increased risk of surgery (OR 1.82, 95% CI 1.14 – 2.91) (Table 2). Exposure to pets, growing up on a farm, or daycare exposure did not modify risk of surgery in CD. Among disease related covariates, as expected, older age at diagnosis was associated with reduced risk of surgery (OR 0.97, 95% CI 0.96 – 0.99) while both stricturing (OR 5.56, 95% CI 2.78 – 11.10) and penetrating phenotypes (OR 5.95, 95% CI 3.28 – 10.79) were associated with increased risk of surgery. On multivariate analysis, adjusting for age at diagnosis, disease duration, location, behavior, presence of perianal disease, and current smoking status, a history of being breastfed (OR 0.21, 95% CI 0.09 – 0.46) remained inversely associated while early life cigarette smoke exposure (OR 2.17, 95% CI 1.10 – 4.29) was associated with increased risk of surgery (Table 2). In a mutually adjusted model including both breastfeeding and childhood cigarette smoke exposure, only breast feeding remaining statistically significant in its inverse association with CD related surgery (OR 0.22, 95% CI 0.10 – 0.49). In exploratory analysis, neither a history of being breast fed nor early life cigarette smoke exposure was associated with anti-TNF use (a history of being breastfed: OR 1.06, 95% CI 0.59 – 1.93; childhood cigarette smoke exposure OR 0.75, 95% CI 0.42 – 1.33), penetrating or stricturing CD, with a specific disease location, or age at diagnosis.
In contrast to the association for CD, we identified no association between early life exposures and need for surgery or biologic therapy in UC (Table 3). Such exposures were also not associated with disease extent except for a weak association between childhood cigarette smoke exposure and pancolitis (OR 3.25, 95% CI 1.02 – 10.34).
Growing literature on genetics and the microbiome supported by data from prospective epidemiologic cohorts suggests an important role for the external environment in incidence and natural history of IBD ,,. Identification of relevant environmental exposures offer the promise of providing clues towards the etiopathogenesis of these complex and disabling diseases, and importantly allow for development of interventions that modify these factors to improve disease outcomes. This study, for the first time examined the association between early life exposures and disease outcome in IBD. Our analysis showed that a history of being breastfed was inversely associated with risk of surgery in CD, while exposure to cigarette smoke during childhood increased this risk independent of current smoking status.
The role of breastfeeding in immunologically mediated diseases has been examined in several prior studies; most have focused on it as a risk factor for incident disease and not on subsequent natural history. The reduction in risk of IBD in those who were breastfed in infancy was proposed in support of the hygiene hypothesis, which linked the rise in incidence of autoimmune disease to improvement in environmental hygiene and reduced exposure to childhood infections . However, the association between a history of being breastfed and risk of incident CD or UC has been inconsistent in the literature. Several studies failed to identify such an association ,- while a Danish cohort suggested a trend towards protective effect . A large population-based case control study by Gearry et al. including over 600 patients each with CD, UC, and healthy controls demonstrated a protective association between breastfeeding and both diseases . Indeed, Corrao et al. demonstrated that lack of breastfeeding during infancy provided the highest population attributable risk for CD in women .
Newly established inception cohorts of CD confirm dysbiosis early on in disease . Prior studies have shown that specific bacteria such as the firmicute Faecalibacterium prausnitzii may be protective against recurrence after surgical resection confirming the central role of enteric microbiota in the development of disease . No prior studies examined the effect of breastfeeding on course of IBD. However, considerable biological plausibility exists to this hypothesis. Breastfeeding exerts one of the strongest influences on the gut microbiome. In an elegant study, Penders et al. sequenced the microbiome of 1,032 infants in the Netherlands and found that those who were exclusively breastfed had reduced colonization with Clostridium difficile, Bacteroides, and Lactobacilli and higher frequency of the protective bifidobacteria . Other studies demonstrated similar changes in the enteric microbiome of breastfed infants ,. This has mechanistic implications for the findings of our present study as specific microbial colonization in infancy such as with C difficile has been associated with increased risk of allergy and atopic disorders ,,. Thus it is plausible that early life factors that influence the establishment of the ‘normal’ microbiome may have persistent effects on immune reactivity, thereby also influencing natural history of chronic inflammatory diseases.
Considerable literature exists regarding the effect of cigarette smoke on CD and UC ,-. It is well recognized that current smoking is a risk factor for incident CD and more aggressive disease course ,-. Passive exposure to cigarette smoke has a similar direction of effect though the magnitude of association is weaker than that existing for personal history of smoking . Our findings suggest that remote exposure even early on in childhood may exert a similar effect on natural history of CD. Several prior studies have suggested childhood exposure to be a risk factor for incident CD or UC , but have not examined it as a risk factor for more aggressive subsequent course. There are a few possible ways through which early exposure to cigarette smoke may exert its effect. First, it may alter the intestinal microbiome composition . It has been consistently demonstrated that early life exposure may have greater and more sustained effects on the gut microbiome than exposures later on in adult life ,,,. Second, cigarette smoke may disrupt protective immune mechanisms by impairing recovery from oxidative stress through its effect on the mononuclear cells . Finally, it is possible that smoking may lead to epigenetic alterations that subsequently influence natural history of disease . All these avenues merit further exploration and may offer important clues to the effect of environment on disease.
There are a few implications of our findings. To our knowledge, it is one of the first studies to demonstrate an association between specific early life environmental influences and subsequent outcomes in CD. The large size of our cohort with detailed exposure and outcome information allowed for sufficient power to test our hypotheses. If confirmed in subsequent cohorts, such studies can offer intriguing clues to pathogenesis and highlight the role of the differentially distributed microbiome species as potentially modifiable targets to improve disease outcomes. Further studies are required to prospectively sequence the microbiome at diagnosis in patients with established disease, ascertain environmental exposures, and examine the association with subsequent disease course. Research is also necessary to examine if this is conditional on host genotype as genetics may influence susceptibility to the environment.
We readily acknowledge several limitations to our study. First, exposure to early life environmental influences was through self-report. However, it is unlikely that self-report of early life risk factors would be susceptible to recall bias. Recall bias owing to differential time since diagnosis is also unlikely as the duration of disease was similar between both groups, and adjusted for in our final multivariate models. Second, we did not have information on duration of breastfeeding, exclusivity of breastfeeding, or age at weaning. Such factors may modify the association between breastfeeding and disease outcomes and merit further exploration. Third, residual confounding is a possibility as in any observational study. Fourth, due to fewer events (surgery) in UC, the statistical power to detect associations may be lower. However, most associations except for daycare exposure did not demonstrate even a trend towards an association. We also did not have information on other factors that have been associated with aggressive disease course including steroid use at diagnosis.
In conclusion, this study identified a history of being breastfed and exposure to cigarette smoke during childhood as environmental factors that may impact the natural course of CD. Further studies that examine these factors in conjunction with changes in the microbiome, epigenetic changes, and gene expression could offer insight into how the natural history of IBD is influenced by such influences, and offer avenues for improving disease outcomes.
Khor B, Gardet A, Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011, 474 (7351): 307-317. 10.1038/nature10209.
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012, 491 (7422): 119-124. 10.1038/nature11582.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012, 142 (1): 46-54. 10.1053/j.gastro.2011.10.001. e42; quiz e30
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011, 140 (6): 1785-1794. 10.1053/j.gastro.2011.01.055.
Williams CN: Does the incidence of IBD increase when persons move from a low- to a high-risk area?. Inflamm Bowel Dis. 2008, 14 (Suppl 2): S41-42. 10.1002/ibd.20562.
Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ: The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014, 15 (3): 382-392. 10.1016/j.chom.2014.02.005.
Kostic AD, Xavier RJ, Gevers D: The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014, 146 (6): 1489-1499. 10.1053/j.gastro.2014.02.009.
Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C: Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012, 13 (9): R79-10.1186/gb-2012-13-9-r79.
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008, 105 (43): 16731-16736. 10.1073/pnas.0804812105.
Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004, 127 (2): 412-421. 10.1053/j.gastro.2004.04.061.
Ananthakrishnan AN: Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol. 2013, 9 (6): 367-374.
Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, Munkholm P: Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohn's Colitis. 2011, 5 (6): 577-584. 10.1016/j.crohns.2011.05.010.
Hlavaty T, Toth J, Koller T, Krajcovicova A, Oravcova S, Zelinkova Z, Huorka M: Smoking, breastfeeding, physical inactivity, contact with animals, and size of the family influence the risk of inflammatory bowel disease: A Slovak case-control study. United Eur Gastroenterol J. 2013, 1 (2): 109-119. 10.1177/2050640613478011.
Bager P, Simonsen J, Nielsen NM, Frisch M: Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012, 18 (5): 857-862. 10.1002/ibd.21805.
Decker E, Engelmann G, Findeisen A, Gerner P, Laass M, Ney D, Posovszky C, Hoy L, Hornef MW: Cesarean delivery is associated with celiac disease but not inflammatory bowel disease in children. Pediatrics. 2010, 125 (6): e1433-1440. 10.1542/peds.2009-2260.
Khalili H, Ananthakrishnan AN, Higuchi LM, Richter JM, Fuchs CS, Chan AT: Early life factors and risk of inflammatory bowel disease in adulthood. Inflamm Bowel Dis. 2013, 19 (3): 542-547. 10.1097/MIB.0b013e31828132f8.
Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE: Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012, 130 (4): e794-803. 10.1542/peds.2011-3886.
Shaw SY, Blanchard JF, Bernstein CN: Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010, 105 (12): 2687-2692. 10.1038/ajg.2010.398.
Ng SC, Tang W, Leong RW, Chen M, Ko Y, Studd C, Niewiadomski O, Bell S, Kamm MA, de Silva HJ, Kasturiratne A, Senanayake YU, Ooi CJ, Ling KL, Ong D, Goh KL, Hilmi I, Ouyang Q, Wang YF, Hu P, Zhu Z, Zeng Z, Wu K, Wang X, Xia B, Li J, Pisespongsa P, Manatsathit S, Aniwan S, Simadibrata M et al: Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 2014.
Goldman AS: The immune system in human milk and the developing infant. Breastfeed Med. 2007, 2 (4): 195-204. 10.1089/bfm.2007.0024.
Hanson LA: Session 1: Feeding and infant development breast-feeding and immune function. Proc Nutr Soc. 2007, 66 (3): 384-396. 10.1017/S0029665107005654.
Rogier EW, Frantz AL, Bruno ME, Wedlund L, Cohen DA, Stromberg AJ, Kaetzel CS: Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc Natl Acad Sci U S A. 2014, 111 (8): 3074-3079. 10.1073/pnas.1315792111.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006, 55 (6): 749-753. 10.1136/gut.2005.082909.
Strachan DP: Hay fever, hygiene, and household size. BMJ. 1989, 299 (6710): 1259-1260. 10.1136/bmj.299.6710.1259.
Castiglione F, Diaferia M, Morace F, Labianca O, Meucci C, Cuomo A, Panarese A, Romano M, Sorrentini I, D'Onofrio C, Caporaso N, Rispo A: Risk factors for inflammatory bowel diseases according to the "hygiene hypothesis": a case-control, multi-centre, prospective study in Southern Italy. J Crohns Colitis. 2012, 6 (3): 324-329. 10.1016/j.crohns.2011.09.003.
Jakobsen C, Paerregaard A, Munkholm P, Wewer V: Environmental factors and risk of developing paediatric inflammatory bowel disease – a population based study 2007–2009. J Crohns Colitis. 2013, 7 (1): 79-88. 10.1016/j.crohns.2012.05.024.
Roberts SE, Wotton CJ, Williams JG, Griffith M, Goldacre MJ: Perinatal and early life risk factors for inflammatory bowel disease. World J Gastroenterol. 2011, 17 (6): 743-749. 10.3748/wjg.v17.i6.743.
Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML: Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010, 25 (2): 325-333. 10.1111/j.1440-1746.2009.06140.x.
Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, Di Paolo M, Riegler G, Rigo GP, Ferrau O, Mansi C, Ingrosso M, Valpiani D: Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol. 1998, 27 (3): 397-404. 10.1093/ije/27.3.397.
Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE: Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006, 118 (2): 511-521. 10.1542/peds.2005-2824.
Azad MB, Konya T, Maughan H, Guttman DS, Field CJ, Chari RS, Sears MR, Becker AB, Scott JA, Kozyrskyj AL: Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months. CMAJ. 2013, 185 (5): 385-394. 10.1503/cmaj.121189.
Fallani M, Young D, Scott J, Norin E, Amarri S, Adam R, Aguilera M, Khanna S, Gil A, Edwards CA, Dore J: Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. J Pediatr Gastroenterol Nutr. 2010, 51 (1): 77-84. 10.1097/MPG.0b013e3181d1b11e.
Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, Stobberingh EE: Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007, 56 (5): 661-667. 10.1136/gut.2006.100164.
Van Nimwegen FA, Penders J, Stobberingh EE, Postma DS, Koppelman GH, Kerkhof M, Reijmerink NE, Dompeling E, van den Brandt PA, Ferreira I, Mommers M, Thijs C: Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol. 2011, 128 (5): e941-943.
Birrenbach T, Bocker U: Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis. 2004, 10 (6): 848-859. 10.1097/00054725-200411000-00019.
Cosnes J: Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004, 18 (3): 481-496. 10.1016/j.bpg.2003.12.003.
Cosnes J: What is the link between the use of tobacco and IBD?. Inflamm Bowel Dis. 2008, 14 (Suppl 2): S14-15. 10.1002/ibd.20555.
Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP: Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996, 110 (2): 424-431. 10.1053/gast.1996.v110.pm8566589.
Cosnes J, Beaugerie L, Carbonnel F, Gendre JP: Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology. 2001, 120 (5): 1093-1099. 10.1053/gast.2001.23231.
Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J: Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther. 1999, 13 (11): 1403-1411. 10.1046/j.1365-2036.1999.00630.x.
van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Dijkstra G: Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009, 15 (8): 1199-1207. 10.1002/ibd.20884.
Mahid SS, Minor KS, Stromberg AJ, Galandiuk S: Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13 (4): 431-438. 10.1002/ibd.20070.
Sandler RS, Sandler DP, McDonnell CW, Wurzelmann JI: Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis. Am J Epidemiol. 1992, 135 (6): 603-608.
Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Prescott NJ, Pessoa-Lopes P, Mathew CG, Sanderson J, Hart AL, Kamm MA, Knight SC, Forbes A, Stagg AJ, Lindsay JO, Whelan K: Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis. 2012, 18 (6): 1092-1100. 10.1002/ibd.21864.
Munyaka PM, Khafipour E, Ghia JE: External influence of early childhood establishment of gut microbiota and subsequent health implications. Front Pediatrics. 2014, 2: 109-10.3389/fped.2014.00109.
Bergeron V, Grondin V, Rajca S, Maubert MA, Pigneur B, Thomas G, Trugnan G, Beaugerie L, Cosnes J, Masliah J, Sokol H, Seksik P, Bachelet M: Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. Inflamm Bowel Dis. 2012, 18 (6): 1101-1111. 10.1002/ibd.21889.
Alegria-Torres JA, Baccarelli A, Bollati V: Epigenetics and lifestyle. Epigenomics. 2011, 3 (3): 267-277. 10.2217/epi.11.22.
We acknowledge the valuable contributions of the participants and the research staff of our registry. This work is supported by the National Institutes of Health (NIH) (P30 DK043351) to the Center for Study of Inflammatory Bowel Diseases. Ananthakrishnan is supported in part by a grant from the National Institutes of Health (K23 DK097142).
The author(s) declare that they have no competing interests.
AYG: study design, data collection, interpretation of data, drafting of the manuscript. BWS, RGW, CNR, MAC, HCS, AT: data collection, critical revision of the manuscript for important intellectual content. DN: data collection, critical revision of the manuscript for important intellectual content. JS: data collection, critical revision of the manuscript for important intellectual content. CG: data collection, critical revision of the manuscript for important intellectual content. HK: data collection, critical revision of the manuscript for important intellectual content. VY: data collection, critical revision of the manuscript for important intellectual content. RX: data collection, critical revision of the manuscript for important intellectual content. AA: study design, data collection, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.